Clinical trial · no report yet · Phase 2
DARE
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- NCT04567420 ↗
- Active, not recruiting
- Criterium, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 20 | |
| Podcasts | 11 | |
| X threads | 9 | |
| Bluesky threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Palbociclib; Fulvestrant; Adjuvant Therapy
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 70 (estimated)
- Primary outcomes
- Surveillance/ctDNA screening Phase
- Therapeutic Phase
- Sponsor
- Criterium, Inc.
- Start
- Feb 9, 2021
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04567420 · updated Oct 15, 2026